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Sphingosine 1-phosphate (S1P), a multifunc-
tional  lipid  mediator  that  signals  via  five  G 
protein–coupled receptors (GPCRs), regulates 
vascular maturation, permeability, and angio-
genesis (Hla, 2004; Cyster, 2005). Recently, 
interest in the roles of S1P and its receptors in 
the immune system has been prompted in part 
by the identification of the immunomodulator 
FTY720  (Brinkmann  et al.,  2002;  Mandala 
et al., 2002; Chiba, 2005), which upon phos-
phorylation by Sphk2 to FTY720-P (Sanchez 
et al.,  2003;  Zemann  et al.,  2006)  acts  as  a 
strong agonist for four out of five S1P recep-
tors  (Brinkmann  et al.,  2004).  FTY720  in-
duces  profound  lymphopenia  by  inhibiting 
the egress of lymphocytes from the thymus, 
peripheral lymph nodes, and Peyer’s patches 
(Chiba, 2005). Indeed, it is now appreciated 
that S1P signaling modulates the trafficking of 
not only naive and central memory T cells, 
but also B cells, dendritic cells, NK cells, os-
teoclasts, and hematopoietic progenitor cells 
(Allende  and  Proia,  2002;  Kabashima  et al., 
2006; Massberg et al., 2007; Schwab and Cyster, 
2007; Walzer et al., 2007; Ledgerwood et al., 
2008; Rivera et al., 2008; Sebzda et al., 2008; 
Ishii et al., 2009). These studies suggest that 
S1P regulates hematopoietic and immune cell 
trafficking under homeostatic and disease con-
ditions; however, it is unclear precisely how 
S1P receptor signaling modulates cellular re-
sponses to egress cues.
The mechanism of how S1P regulates T cell 
trafficking  has  been  intensively  investigated; 
T cell–specific deletion of S1p1r or hematopoi-
etic reconstitution using S1p1r/ fetal liver 
cells  resulted  in  profound  lymphopenia,  sug-
gesting that the T cell–intrinsic S1P receptor 1 
(S1P1) is essential for their egress from the thy-
mus and secondary lymph nodes (Allende et al., 
2004; Matloubian et al., 2004). This observa-
tion, coupled with the finding that FTY720-P 
induces the loss of cell-surface S1P1 from lym-
phocytes in an irreversible manner (Gräler and 
Goetzl, 2004; Matloubian et al., 2004), suggests 
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The sphingosine 1-phosphate receptor 1 (S1P1) promotes lymphocyte egress from lymphoid 
organs. Previous work showed that agonist-induced internalization of this G protein–
coupled receptor correlates with inhibition of lymphocyte egress and results in lymphope-
nia. However, it is unclear if S1P1 internalization is necessary for this effect. We 
characterize a knockin mouse (S1p1rS5A/S5A) in which the C-terminal serine-rich S1P1 motif, 
which is important for S1P1 internalization but dispensable for S1P1 signaling, is mutated. 
T cells expressing the mutant S1P1 showed delayed S1P1 internalization and defective 
desensitization after agonist stimulation. Mutant mice exhibited significantly delayed 
lymphopenia after S1P1 agonist administration or disruption of the vascular S1P gradient. 
Adoptive transfer experiments demonstrated that mutant S1P1 expression in lymphocytes, 
rather than endothelial cells, facilitated this delay in lymphopenia. Thus, cell-surface resi-
dency of S1P1 on T cells is a primary determinant of lymphocyte egress kinetics in vivo.
©  2010  Thangada  et al.  This  article  is  distributed  under  the  terms  of  an   
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six 
months after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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case of S1P1, it is unknown whether internalization is required 
for lymphocyte egress and recirculation.
To address the role of S1P1 internalization in the control of 
lymphocyte egress during homeostasis and FTY720 treatment, 
we developed a mouse model in which WT S1P1 is replaced by 
the internalization-deficient mutant (S5A-S1P1). We show that 
although T cell trafficking under homeostasis is unaltered, 
S1p1rS5A/S5A mice display kinetic resistance to lymphopenia in-
duced by the S1P1 modulator (FTY720-P) or disruption of the 
S1P gradient. Adoptive transfer of S1p1rWT/WT and S1p1rS5A/S5A  
lymphocytes and S1P1 surface staining of lymph node endo-
thelial cells demonstrate that the T cell S1P1, and not endothe-
lial cell S1P1 expression, regulates the rate of lymphocyte egress 
in vivo. These data support a T cell–intrinsic model of S1P1 
signaling in egress kinetics wherein the internalization of S1P1 
is a crucial modulator of the cues for T cell migration.
RESULTS
Derivation of the S1p1rS5A/S5A mouse strain
To determine the in vivo role of S1P1 internalization in receptor 
function, we generated a knockin mouse expressing a mutant   
internalization-deficient S1P1 under the control of its natural pro-
moter. Specifically, we replaced the five clustered C-terminal tail 
serine residues, which are known to be phosphorylated upon 
agonist-induced desensitization with nonphosphorylatable 
alanines (Oo et al., 2007). This mutant S5A-S1P1 was expressed 
efficiently on the cell surface of transfected HEK293 cells and 
displayed decreased internalization kinetics compared with WT 
S1P1 in response to FTY720-P or S1P treatment (Oo et al., 2007). 
However, the kinetics of S5A-S1P1 signaling was similar to WT 
S1P1, as demonstrated by extracellular signal-regulated kinase 
(ERK) phosphorylation assays in transfected cells (Fig. S1). This 
is consistent with previous studies from our laboratory showing 
that deletion of the C-terminal tail of S1P1 did not interfere 
with ligand binding or signal transduction (Liu et al., 1999).
Given that the S5A-S1P1 exhibits a specific deficiency in 
ligand-induced internalization but not G protein–dependent 
signaling, we rationalized that this mutant receptor would 
demonstrate extended cell-surface residency as compared with 
the WT receptor, even after agonist-induced activation, and 
would therefore reveal phenotypes that depend on receptor 
internalization.  Thus,  the  corresponding  mutation  was 
knocked into the genome of mouse embryonic stem (ES) 
cells by homologous recombination. The resulting ES cells 
were used to derive chimeric mice, which were then bred to 
homozygosity and backcrossed five to six generations onto 
the C57BL/6 background. Sequence analysis of genomic DNA 
from S1p1rS5A/S5A mice showed that the corresponding muta-
tion was knocked in to the genome (Fig. 1). The S1p1
S5A/S5A 
mice were viable, reproduced normally, and gave rise to healthy 
offspring. This suggests that the development of the vascular 
system was not perturbed in the S1p1rS5A/S5A mice.
Delayed internalization of S5A-S1P1 after FTY720 treatment
We next examined the cell-surface expression of S1P1 in vivo 
in lymph node and thymic T cells. Mice were treated with 
that functional antagonism of S1P1 in the lymphocyte com-
partment is essential for the inhibition of T cell egress.
However, other studies have led to the proposal of an   
alternative mechanism by which S1P1 regulates lymphocyte 
egress. Immunofluorescence microscopy demonstrated high 
expression levels of S1P1 in endothelial cells, whereas staining 
of lymphocytes was weaker (Singer et al., 2005; Sinha et al., 
2009). Moreover, administration of SEW2971, a selective 
S1P1 agonist, does not induce irreversible receptor loss from 
the cell surface but causes significant lymphopenia in vivo   
(Jo et al., 2005). Two-photon microscopy of explanted lymph 
nodes containing labeled lymphocytes suggested that S1P1 ag-
onists may modulate barrier function and closure of vascular 
portals in the medulla, through which T cells egress into effer-
ent lymphatics (Wei et al., 2005). Thus, this alternative proposal 
favors endothelial cells as the primary target cell type for S1P1 
agonists to inhibit lymphocyte egress (Rosen et al., 2008).
Close  interactions  between  immune  and  vascular  cells 
may  underlie  the  ability  of  S1P1  to  promote  lymphocyte 
egress. In lymph node cortical sinuses, egress of T and B cells 
required S1P1-dependent transendothelial traverse (Grigorova 
et al., 2009; Sinha et al., 2009). Indeed, competing chemo-
tactic signaling between the egress-promoting S1P–S1P1  
system and the retention-promoting CXCL21–CCR7 che-
mokine receptor system of T cells appears to determine the 
rate and extent of their egress from secondary lymphoid or-
gans (Pham et al., 2008). Whether S1P1 signaling in lympho-
cytes, endothelial compartments, or both is important in the 
process of egress is not known.
S1P1 is a type I GPCR that is rapidly phosphorylated 
upon agonist stimulation. Although several protein kinases 
are involved in the phosphorylation of S1P1 (Lee et al., 
2001), phosphorylation at the C-terminal domain is particu-
larly relevant to receptor desensitization and internalization 
(Hla, 2001). Because FTY720-P is degraded less efficiently 
than S1P by S1P lyase and S1P phosphatases (Bandhuvula 
et al., 2005; Mechtcheriakova et al., 2007; Yamanaka et al., 
2008), its ligation likely induces sustained receptor activation 
kinetics. Presumably, this underlies the FTY720-P–induced 
irreversible internalization and proteosomal degradation of 
S1P1 and resultant lymphopenia (Oo et al., 2007). The GRK-2 
enzyme is capable of phosphorylating the serine-rich motif 
in the C-terminal tail of S1P1 (Watterson et al., 2002), and 
we recently demonstrated that mutation of the five serines 
in the C terminus of S1P1 to nonphosphorylatable alanines 
inhibited S1P- and FTY720-P–induced receptor internal-
ization in transfected HEK293 cells (Oo et al., 2007). Al-
though previous studies of GPCR signaling and chemotaxis 
have provided some insights into the role of internalization in 
these processes, the results appear to be receptor specific. For   
example, a CXCR4 superagonist induced greater chemotaxis 
than the native ligand stromal cell–derived factor–1 (SDF-1)   
with no perceptible receptor internalization (Sachpatzidis et al., 
2003). Conversely, mutations in the C terminus of CXCR2 
resulted in defective receptor internalization concomitant 
with impaired chemotaxis (Sachpatzidis et al., 2003). In the JEM VOL. 207, July 5, 2010 
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ceptor agonist (Fig. 3). This phenotype 
was more pronounced in response to 
FTY720-P  than  to  S1P,  consistent 
with the fact that FTY720-P induces 
more effective receptor internalization 
in WT cells. In contrast, both WT 
and  mutant  cells  responded  to  other 
chemokines—CXCL12  (SDF-1)  and 
CCL21—in a similar manner, sug-
gesting that the lack of desensitization 
in the S5A-S1P1 cells is specific for 
S1P1 and not a general effect on other 
chemotactic GPCRs.
To  further  establish  the  involve-
ment  of  altered  receptor  desensitiza-
tion in S5A-S1P1 cells, WT and mutant mice were treated 
with FTY720 and ex vivo receptor-activated Gi responses 
were quantified 2 h later. S1P1 activation was measured by 
quantifying intracellular cAMP levels after ex vivo stimula-
tion of T cells with forskolin (a direct activator of adenylate 
cyclase), IBMX (3-isobutyl-1-methylxanthine; a phospho-
diesterase inhibitor), and AUY954 (an S1P1-specific agonist; 
Pan et al., 2006). As shown in Fig. 4, WT S1P1 was effec-
tively desensitized in vivo, as these cells did not display a 
decrease in cAMP, indicative of S1P1 agonist-activated Gi 
responses. Conversely, S5A-S1P1 cells exhibited robust Gi 
activation in response to S1P1 agonism with AUY954. These 
data establish that in sharp contrast to WT S1P1, S5A-S1P1 is 
not desensitized after exposure to FTY720-P in vivo.
The S5A-S1P1 mutation exhibits delayed lymphopenia kinetics
Lymphoid architecture can be altered as a result of changes to 
cell homing and migration within the structures (Weninger 
and von Andrian, 2003). To identify any alterations in the 
T cell compartment of lymphoid organs in S1p1rS5A/S5A mice, 
lymph node structures were compared between S1p1
WT/WT 
and S1p1
S5A/S5A mice by immunofluorescence microscopy. 
As shown in Fig. S2, B cell follicles (B220+), T cell zones 
(CD4+, CD8+), LYVE-1+ lymphatic vessels, platelet/endo-
thelial cell adhesion molecule 1+ (PECAM-1+) high endo-
thelial venules, and dendritic cell (CD11c+) staining were 
similar. Thymic architecture was also similar, suggesting that 
the S5A-S1P1 mutation had no discernable impact on the de-
velopment of primary or secondary lymphoid organ architec-
ture. Flow cytometric analysis of T cells from both S1p1rWT/WT 
and S1p1rS5A/S5A mice revealed similar numbers of CD4+CD8+ 
FTY720, which is rapidly converted to FTY720-P (Mandala 
et al., 2002; Brinkmann et al., 2004). Lymphocytes were iso-
lated from mice treated with FTY720 for 0, 2, or 24 h, and 
expression of T cell–surface S1P1 was assessed by flow cytom-
etry using an antibody specific for S1P1 (Pham et al., 2008). 
As shown in Fig. 2, WT T cells expressed significant levels of 
S1P1 on the cell surface. 2 h after FTY720 treatment, the re-
ceptor was not detectable on WT T cells, suggesting that it 
was internalized (Fig. 2, A and C). In sharp contrast, FTY720-
treated S5A-S1P1 T cells showed robust receptor expression 
on the cell surface. Similar results were obtained using thymic 
T cells (Fig. 2, B and D). 24 h after FTY720 treatment, sur-
face S1P1 staining was not detectable on either WT or mutant 
lymph node or thymic T cells (Fig. 2, E and F). At no time 
was the S1P1 detected on the surface of peripheral blood 
T cells (unpublished data). These data suggest that surface ex-
pression of S1P1 under homeostatic conditions is not affected 
by the S5A mutation. However, the internalization rate of 
mutant S5A-S1P1 is significantly slower than that of the WT 
counterpart upon FTY720 treatment in vivo.
Sustained chemotactic response of S5A-S1P1 T cells
Next, we tested the ability of lymphocytes isolated from WT 
and S5A-S1P1 mutant mice to respond to chemotactic stimuli, 
including agonists of S1P1. Both WT and mutant lympho-
cytes migrated toward S1P and FTY720-P. However, at high 
doses of both S1P and FTY720-P, mutant cells displayed per-
sistent cell migration, whereas the WT counterparts were 
refractory to continued chemotactic stimulation. Thus, a 
bell-shaped response was obtained in WT cells, whereas mu-
tant cells exhibited a sigmoidal response at high doses of re-
Figure 1.  Construction of the S1p1rS5A/S5A 
mice. (A) Schematic representation of the 
S5A-S1P1 knockin construct. E, EcoRI; Ex, 
exon; H, HindIII. (B) Genotyping analysis of 
tail DNA. (C) DNA sequence of the mutated 
site from the tail DNA of S1p1S5A/S5A mice. 
Nucleotides are represented by black (G), blue 
(C), green (A), and red (T), with each respective 
codon shown above.1478 S1P1: location, location, location | Thangada et al.
slight expansion of the CD4+ and CD8+ compartments in the 
spleens of S1p1
S5A/S5A mice.
Although homeostatic T cell trafficking appeared to be 
unchanged,  an  effect  on  T cell  transit  into  lymph  nodes 
could not be ruled out. To address the possibility that the 
S5A mutation was altering lymphocyte homing into the lymph 
node, fluorescently labeled S1p1
WT/WT and S1p1
S5A/S5A sple-
nocytes were transferred into naive WT mice treated with 
integrin-blocking antibodies (Lo et al., 2003; Pham et al., 
2008). We did not observe a difference in the fraction of 
transferred lymphocytes retained in the lymph nodes 8 h   
after integrin blockade (Fig. S9), suggesting that lymphocyte 
egress from lymph nodes under homeostasis is not affected 
by the S5A-S1P1 mutation.
Given that S1P1 is critical for the inhibition of lymphocyte 
egress resulting in FTY720-induced lymphopenia, we com-
pared the kinetics of the lymphopenic response in WT and 
S5A-S1P1 mice. As shown in Fig. 5 A, treatment of mice with 
0.5 mg/kg FTY720 led to a rapid decrease in CD4+ and CD8+ 
cells in the blood of WT mice. In contrast, the disappearance 
rate of blood CD4+ and CD8+ cells in the mutant mice was 
significantly slower. The lymphopenic response was main-
tained in WT mice for up to 120 h. In contrast, the recovery 
of CD4+ and CD8+ cells in the blood to untreated levels oc-
curred much more rapidly in S5A-S1P1 mice compared with 
their WT counterparts. To confirm that S1P1 was responsi-
ble for these effects, we treated mice with the S1P1-specific   
agonist AUY954 (Pan et al., 2006). We observed that lym-
phopenia kinetics were significantly delayed, attenuated, and 
recovered faster in S5A-S1P1 mice compared with the WT 
counterparts (Fig. 5 B). These data indicate that S1P1 internal-
ization in vivo plays a direct role in the inhibition of lympho-
cyte egress from lymphoid organs into the circulation.
Although S1P1 internalization was clearly required for the 
inhibition of T cell egress in response to FTY720 treatment, 
we asked whether the S5A mutation would display altered 
kinetics in response to the natural agonist, S1P. Inhibition of 
S1P lyase with 2-acetyl-4-tetrahydroxybutylimidazole (THI) 
increases S1P concentrations, thereby disrupting the S1P gra-
dient between vascular and extravascular spaces, and results in 
profound lymphopenia by blocking lymphocyte egress (Schwab 
et al., 2005). To obtain further evidence for the role of S1P1 
internalization in effecting lymphocyte egress, we increased 
S1P concentrations by THI treatment in WT and S5A-S1P1 
mice. As shown in Fig. 5 C, S1p1
WT/WT mice demonstrated a 
dramatic disappearance of both CD4+ and CD8+ T cells from 
circulating blood within 24 h of THI treatment. In sharp   
contrast, S1p1
S5A/S5A mice exhibited a strong resistance to 
THI-induced lymphopenia, suggesting that receptor internal-
ization is critical for the response to the natural S1P1 ligand, as 
well as to FTY720 agonism.
Lymphocyte but not vascular S1P1 is critical for determining 
egress kinetics
Because of the competing models regarding the respective 
roles of vascular versus lymphoid S1P1 expression in the 
double-positive, CD4CD8 double-negative, and CD4+ 
and CD8+ single-positive (SP) T cells in the thymus, suggest-
ing that T cell development is normal in S1p1
S5A/S5A mice 
under homeostatic conditions (Fig. S3).
In the spleen, SP C4+ and SP CD8+ cell numbers were 
modestly elevated in S1p1rS5A/S5A mice, whereas no signifi-
cant differences were found in the numbers of circulating 
blood or lymph node and lung tissue SP CD4+ or CD8+ cells. 
Expression of the lymphocyte maturation and activation 
markers CD69, CD44, CD25, and CD24 in the thymus; 
CD69, CD44, and CD11a in the lymph node, spleen, and 
lung; and CD69, CD62L, and CD11a in blood were indistin-
guishable between S1p1
WT/WT and S1p1
S5A/S5A mice (Figs. S4, 
S5, S6, S7, and S8). Collectively, these data suggest that T cell 
development was largely unaffected by the S5A-S1P1 muta-
tion. T cell numbers, maturation, and activation states in dif-
ferent compartments were largely unchanged, except for a 
Figure 2.  Slow internalization of S1P1 in vivo. (A–D) Internaliza-
tion of S5A-S1P1 is delayed in vivo in T cells from the lymph nodes  
(A and B) and thymus (C and D). S1P1 levels on CD4+CD62Lhi cells are 
shown. S1p1WT/WT (WT) and S1p1S5A/S5A (S5A) mice were untreated or 
treated with 0.5 mg/kg FTY720, and 2 h later cells were stained with the 
S1P1-specific antibody. Blue tracings show untreated cells, red tracings 
show FTY720-treated cells, and gray graphs show staining with nonimmune 
serum (NIS). (E and F) S1P1 staining in lymph node cells (E) and thymocytes 
(F) isolated from WT and S5A mice 24 h after FTY720 treatment. Green 
tracings show WT cells, blue tracings show S5A cells, and gray graphs 
show staining with nonimmune serum. Surface S1P1 staining was not de-
tectable in either WT or S5A cells. Data represent FACScan profiles from a 
typical experiment that was repeated twice with similar results.JEM VOL. 207, July 5, 2010 
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lymphopenia at 2 h when transferred into WT recipients, 
and WT T cells transferred into mutant animals would 
demonstrate faster kinetics of lymphopenia. Conversely, 
if the endothelial S1P1 was the major determinant, then 
WT T cells transferred into mutant recipients would 
exhibit  resistance  to  FTY720  treatment  and  mutant 
T cells in WT recipients would demonstrate the rapid 
lymphopenia response. As shown in Fig. 6, S5A-S1P1 
total lymphocytes (A and B) or CD4+ T cells (C and D) 
were not responsive to FTY720 when transferred into 
the WT or mutant backgrounds, whereas WT lympho-
cytes or T cells responded equally well to FTY720 in both 
WT and mutant recipients. Furthermore, examination of S1P1 
expression on lymph node endothelial cells demonstrated that 
although WT surface S1P1 was dramatically reduced within 2 h 
and remained low for 24 h after FTY720 treatment, endothelial 
cells expressing tS5A-S1P1 displayed resistance to surface down-
regulation that quickly recovered to pretreatment levels   
(Fig. S10). Thus, the S5A-S1P1 mutation in the vascular ele-
ments did not influence lymphocyte egress rates, suggesting that 
the rate of S1P1 internalization on T cells is the primary determi-
nant of lymphopenia kinetics in vivo.
DISCUSSION
The S1P–S1P1 signaling axis represents one of the most criti-
cal regulators of lymphocyte trafficking, yet little is known 
about the in vivo dynamics of S1P1 in response to ligand bind-
ing. Studies have identified a cyclical pattern of lymphocyte 
S1P1 expression: increased in lymphoid organs, decreased or 
absent in peripheral circulation. However, the signaling prop-
erties within this pattern, i.e., whether S1P1 surface expression 
is a necessary determinant of lymphoid residence, have been 
difficult to elucidate in the in vivo context. The diversity of 
GPCR signal regulation further complicates the issue.  Agonist-
induced internalization of GPCRs is believed to be im-
portant in a variety of signaling modalities (Hanyaloglu and 
von Zastrow, 2008; Marchese et al., 2008). In the case of some 
receptors, cells become unresponsive to agonists after a signifi-
cant fraction of receptors are internalized (Vroon et al., 2006). 
Additionally, endocytosed receptors may carry out unique   
signaling functions in the different subcellular compartments 
(i.e., early versus late endosome; Hanyaloglu and von Zastrow, 
2008; Marchese et al., 2008). Although S1P1 is known to un-
dergo agonist-induced surface down-regulation, it is unclear 
what functional consequences result from this event.
modulation of lymphocyte egress, we sought to determine 
whether  the  effect  on  lymphopenia  kinetics  observed  in 
S5A-S1P1 cells could be attributed to T cell or endothelial 
cell expression of S1P1. We performed adoptive transfer of 
CFSE-labeled WT or S5A-S1P1 bulk lymphocytes into re-
cipient  WT  or  mutant  mice  and  measured  the  effect  of 
FTY720 administration on T cell numbers in the blood. If 
T cell S1P1 surface residency determines egress rates, then 
mutant  T cells  would  be  resistant  to  FTY720-induced   
Figure 3.  Lymphocytes bearing S5A-S1P1 show aberrant che-
motactic response to S1P1 agonists. (A–D) Lymphocytes were 
isolated from lymph nodes of S1p1WT/WT and S1p1S5A/S5A mice and 
were stimulated with S1P (A), FTY720-P (B), SDF-1 (C), or CCL21  
(D) in a chemotaxis assay as described in Materials and methods (n = 3; 
*, P < 0.01). Values are expressed as the percentage of cells that 
migrate at the given concentration of chemoattractant compared 
with the number of cells that migrate in the absence of chemo-
attractant after 3 h at 37°C. Data are means ± SE and are repre-
sentative of two experiments performed.
Figure 4.  Defective desensitization of the mutant S5A-S1P1. 
S1p1WT/WT and S1p1S5A/S5A mice were treated with 0.5 mg/kg FTY720 or 
vehicle, and 2 h later thymocytes were isolated. Cells were incubated with 
the adenylate cyclase activator forskolin (FSK) and the phosphodiesterase 
inhibitor IBMX in the presence or absence of 10 or 100 nM of the S1P1-
specific agonist AUY954 for 15 min as described in Materials and meth-
ods. Intracellular cAMP concentrations were quantified by ELISA (n = 4;  
**, P < 0.01) and are expressed as picomoles per 106 cells. Error bars repre-
sent means ± SE. Data are representative of two experiments performed.1480 S1P1: location, location, location | Thangada et al.
In this study, we demonstrate that the C-terminal serine 
cluster, which corresponds to the GRK-2 phosphorylation site 
(Watterson et al., 2002; Oo et al., 2007), is important in vivo 
for determining the rate of internalization of S1P1 in T cells 
after FTY720 administration. In contrast, the receptor level on 
the surface of T cells under homeostatic conditions (high plasma 
S1P levels) was not affected by the S5A mutation. Similarly, 
ligand-induced activation of the ERK signaling pathway is not 
dependent on receptor internalization, because S5A-S1P1–
expressing  cells  exhibited  kinetics  of  ERK  phosphorylation 
similar to those of WT cells. Although the S5A-S1P1 mutant 
showed delayed internalization at 2 h after FTY720 treatment, 
it was undetectable on the surface of T cells by 24 h after FTY720 
treatment, suggesting that additional posttranslational modifica-
tions on the receptor mediate endocytic events.
GPCR signals are the primary modulators of T cell lym-
phoid transit (Pham et al., 2008). In vitro studies using T cells 
demonstrated that S5A-S1P1 did not undergo agonist-induced 
desensitization at high ligand concentrations, as illustrated by 
the linear curve of the chemotaxis responses to both FTY720-P 
and the natural ligand S1P. Similarly, T cells from FTY720-
treated mice did not show agonist-induced desensitization in 
cAMP levels. These observations suggest that receptor internal-
ization limits cellular responses during supramaximal agonism.
Changes in lymphocyte homing can alter the architecture 
of the lymphoid organs and the cognate vasculature. The 
S1p1S5A/S5A mice did not exhibit developmental or structural 
Figure 5.  S5A-S1P1 animals exhibit de-
layed lymphopenia. (A and B) S1p1WT/WT and 
S1p1S5A/S5A mice were treated with either  
0.5 mg/kg FTY720 (A) or 1 mg/kg AUY954 (B).  
Peripheral blood samples were collected from 
mice at various time points and were processed 
for FACS analysis. (n = 3; *, P < 0.05; **, P < 0.01). 
Values are expressed as a percentage of the 
number of CD4+ (top) or CD8+ (bottom) cells at 
each time point compared with untreated values. 
Symbols represent means ± SE. Data are repre-
sentative of two experiments. (C) 10 mg/kg THI 
was administered to WT and S5A mice by oral 
gavage; peripheral blood was collected at 0, 2, 
8, and 24 h after treatment; and cells were 
processed for FACS analysis as described in 
Materials and methods. Values are expressed as 
the percentage of CD4+ (left) or CD8+ (right) 
detected in peripheral blood at the indi-
cated time point after THI treatment as  
compared with untreated controls (n = 3;  
*, P < 0.05; **, P < 0.01). Error bars represent 
means ± SE and are representative of three 
experiments performed.
defects in the vascular or immune sys-
tems,  indicating  that  changes  in  the 
rate  of  S1P1  internalization  do  not 
result in gross signaling defects. Fur-
thermore,  homeostatic  trafficking  of 
T cells was not significantly different between S1p1WT/WT 
and S1p1S5A/S5A mice, as demonstrated by cell retention rates 
within lymph nodes after integrin blockade. In sharp contrast, 
lymphopenia  induced  by  the  S1P1  agonists  FTY720  and 
AUY954 was substantially blunted. Additionally, we assessed 
the response of S5A-S1P1 animals to THI administration, an 
inhibitor of S1P lyase known to increase S1P levels in lym-
phoid organs and disrupt the S1P gradient essential for normal 
lymphocyte egress (Schwab et al., 2005). Although S1p1WT/WT  
mice exhibit profound lymphopenia after THI administra-
tion, the S1p1S5A/S5A animals were refractory to THI-induced 
lymphopenia, suggesting that THI-induced supraphysiologi-
cal S1P levels in the lymphoid organs suppress lymphocyte 
egress by inducing S1P1 internalization. These observations 
suggest that the primary function of S1P1 internalization is to 
limit exaggerated receptor signaling at supramaximal agonist 
activation. In addition, the concept that the S1P1 level on the 
plasma membrane is important in efficient egress of T cells   
is reinforced.
Given that S5A-S1P1 exhibits a clear difference in lym-
phocyte egress kinetics in response to FTY720 treatment,   
we wished to clarify whether S1P1 function in the lympho-
cyte or endothelial cell compartment is critical to the deter-
mination of egress kinetics. Adoptive transfer experiments 
indicated that S5A-S1P1 T cells were refractory to FTY720-
induced lymphopenia, even when transferred into WT hosts. 
Furthermore, S1P1 surface staining of lymph node endothelial JEM VOL. 207, July 5, 2010 
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a mechanism that may be important in the regulation of lym-
phocyte egress in pathological conditions. The finding that 
supraphysiological agonism is necessary to visualize a differ-
ence in trafficking by cells expressing S5A-S1P1, whether 
with FTY720 or the elevation of S1P concentrations by 
THI, is of considerable importance physiologically, not only 
in the context of FTY720, which has completed phase III 
clinical trials for the treatment of multiple sclerosis (Cohen 
et al., 2010), but also in numerous other inflammatory dis-
ease states. Changes in S1P concentrations in blood and at 
tissue-specific sites accompany many diseases, such as coro-
nary artery disease, asthma, rheumatoid arthritis, and certain 
cancers (Ammit et al., 2001; Deutschman et al., 2003; Kitano 
et al., 2006; Bandhuvula and Saba, 2007). During these con-
ditions, exaggerated production of S1P and subsequent sig-
naling may be limited by receptor internalization. We anticipate 
that further studies examining the role of S1P1 trafficking in 
various physiological and pathological contexts may be re-
vealed by this novel mouse model.
MATERIALS AND METHODS
Generation of S1p1S5A/S5A mice. Using a homologous recombineering 
method with mouse genomic bacterial artificial chromosomes (Liu et al., 
2003), a mutant S1P1 (SRSKSDNSS to ARAKADNAA) was constructed 
and introduced into 129S6 × C57BL/6 F1 hybrid ES cells by homologous 
recombination. Positive ES cell clones were used to derive chimeric mice. 
Genotyping analysis by PCR and gene sequencing confirmed that the mu-
tant S1p1r gene was linked to the loxP site 290 bp downstream of exon 2. 
To identify the S1P1 WT (S1p1WT/WT) and mutant S1p1S5A/S5A by PCR, the 
following primers were used: P1, 5-AAGTGCAGTGAGGCCAAACA-3; 
and  P2,  5-GCAAGCATGAGGCAAGTCTA-3.  P1  and  P2  amplify  a 
282-bp fragment for the WT allele and a 376-bp fragment for the S5A allele. 
S1p1
WT/WT and S1p1
S5A/S5A mice were backcrossed onto the C57BL/6 back-
ground for at least five generations. Protocols were approved by the Institu-
tional Animal Care and Use Committees of the University of Connecticut 
Health Sciences Center and Weill Cornell Medical College.
Agonist, antagonist, and inhibitor treatments. 6–8-wk-old WT and 
S5A-S1P1 animals were treated by oral gavage with 0.5 mg/kg FTY720   
or  1  mg/kg  AUY954  in  2%  2-hydoxypropyl--cyclodextrin  (Sigma- 
Aldrich). Control animals received 2% 2-hydoxypropyl--cyclodextrin in 
water. For S1P lyase inhibition, animals were treated by oral gavage with 
10 mg/kg THI dissolved in water, and peripheral blood was collected at 
the time points after treatment indicated in the figures. Control animals 
were gavaged with water alone.
Lymphocyte  chemotaxis  assay.  The  chemotactic  response  of  lymph 
node cells isolated from S1p1
WT/WT and S1p1
S5A/S5A mice to S1P (Enzo Life 
Sciences, Inc.), SDF-1 (R&D Systems), CCL21 (R&D Systems), and 
FTY720-P (provided by Novartis, Basel, Switzerland) were studied using a 
Boyden chamber with 5-µm polycarbonate filters (Neuro Probe). Lymph 
node cell suspensions (500,000 cells/300 µl/well) in RPMI 1640 medium 
supplemented with 0.1% fatty acid–free BSA (Sigma-Aldrich) were added to 
the top chamber. The bottom chambers contained different concentrations 
of the chemoattractants prepared in RPMI/fatty acid–free BSA. Wells con-
taining medium without chemoattractants were used as controls. After 3 h at 
37°C, cells in the bottom chamber were enumerated in a cell and particle 
counter (Beckman Coulter).
Flow cytometry. At the time points after treatment indicated in the fig-
ures, thymus, spleen, lung, or peripheral lymph nodes were dissected and 
mechanically disaggregated in FACS buffer (PBS with 0.1% FBS and 0.1% 
sodium azide), and single-cell suspensions were obtained using a 40-µm cell 
cells isolated from FTY720-treated S1p1S5A/S5A animals re-
vealed that the mutant receptor undergoes minimal down-
regulation by 24 h, in contrast to the receptor on T cells, 
consistent with the idea that the lymphocyte and not endo-
thelial cell S1P1 modulates egress inhibition by FTY720. Re-
cent work has shown that lymphocyte egress from lymph 
nodes occurs at cortical sinuses, where lymphocytes exhibit a 
“probing” behavior dependent on S1P1 activation, and that 
agonism of the receptor is necessary for the successful traverse 
of the lymphocyte between the lymphatic endothelial cells 
that line the cortical sinusoids (Grigorova et al., 2009; Sinha 
et al., 2009). Studies of the leukocyte extravasation suggest 
that a specific membrane domain termed lateral border re-
cycling compartment, which contains PECAM and CD99,   
is critical in the transcytotic process (Mamdouh et al., 2009; 
Muller, 2009). Whether S1P1 signaling utilizes a similar pro-
cess is unknown and should be the subject of future investi-
gations. Nevertheless, our data suggest that upon FTY720 
administration, accumulation of FTY720-P in the lymphoid 
tissue, followed by sustained internalization of S1P1 in the 
lymphocyte compartment, is needed to arrest egress and gen-
erate lymphopenia.
In summary, with the ability to dissect signaling versus 
internalization of S1P1 in the context of lymphocyte hom-
ing, these studies demonstrate that internalization of S1P1 
makes a profound impact on lymphopenia kinetics in vivo,   
Figure 6.  Lymphocyte but not vascular S1P1 is critical in deter-
mining egress kinetics. (A–D) 107 lymphocytes from S1p1WT/WT and 
S1p1S5A/S5A mice were labeled with CFSE and injected i.v. into mice of 
the indicated genotype. 24 h later, mice were treated with 0.5 mg/kg 
FTY720, and 2 h later, peripheral blood was collected and analyzed by 
FACS for total CFSE (A and B) or CD4+ CFSE+ (C and D). Data are repre-
sented as the ratio of FTY720-treated to vehicle-treated mice (n = 3;  
*, P < 0.05; **, P < 0.01; ***, P < 0.001). Data are from one representative 
experiment out of three.1482 S1P1: location, location, location | Thangada et al.
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